Restylane Volyme 1x1ml
Important Notice
Regulated medical device (EU MDR 2017/745). For sale exclusively to qualified healthcare professionals.
What this purchase includes
- Original productFrom the manufacturer or an official distributor, CE marked.
- Batch and expiry documentedRecorded per unit on the delivery note and the invoice.
- Controlled storageOur own Madrid warehouse, 12 to 18 °C under 24 h control.
- Dispatch in 24 to 48 hFrom Madrid, insured and with a tracking number.
- Reachable Monday to Friday9:00 to 17:00 by WhatsApp and email. People, not forms.
Restylane Volyme is Galderma's OBT™ gel intended for volume augmentation of the cheekbone. Unlike the rest of the OBT family, which works in the dermis, Volyme is implanted in the supraperiosteal or subcutaneous plane. With a G′ of 171 Pa and a deformability of 930 %, it provides volume while preserving the flexibility of the midface in movement.
- Cross-linked HA 20 mg/ml
- Lidocaine 3 mg/ml (0.3 %)
- Technology OBT™ / XpresHAn™
- Contents 1 syringe × 1.0 ml
- Needles 2 × 27G ½" UTW
Composition and technology
- Cross-linked hyaluronic acid: 20 mg/ml, of non-animal origin, in phosphate buffer solution at pH 7.
- Lidocaine hydrochloride: 3 mg/ml.
- OBT™ technology (Optimal Balance Technology): continuous, flexible gel. Volyme is the OBT variant formulated to work in depth, not in the dermis.
- Rheological profile: G′ 171 Pa at 0.1 Hz and deformability (xStrain) of 930 %. Compared with the NASHA approach to the same territory (Restylane Lyft, G′ 799 Pa), Volyme sacrifices projection in exchange for a much more flexible behaviour under facial expression.
Position within the range: NASHA and OBT
The entire Restylane range is built on two distinct gel technologies. Choosing between them is the first clinical decision of the treatment.
NASHA® (Non-Animal Stabilized Hyaluronic Acid): firm, particulate gels that retain the long hyaluronic acid chains with minimal cross-linking. High resistance and very low strain tolerance: projection, definition and structural support in areas that must hold their shape.
OBT™ (Optimal Balance Technology, marketed as XpresHAn Technology™ in the United States): soft, flexible gels with a variable degree of cross-linking. Low to intermediate resistance and high strain tolerance: the gel follows the movement of the tissue, which is why it is intended for dynamic and expressive areas.
| NASHA — firmness and projection | G′ 416–799 Pa · deformability 7–19 % |
|---|---|
| Restylane / Classyc Lidocaine | HA 20 mg/ml · G′ 701 Pa · 7 % — wrinkles in the mid dermis, lips |
| Restylane Lyft Lidocaine | HA 20 mg/ml · G′ 799 Pa · 17 % — cheekbones, midface, dorsum of the hands |
| Restylane Eyelight | HA 20 mg/ml — infraorbital hollowing, supraperiosteal plane |
| Restylane Skinboosters Vital / Vital Light | HA 20 and 12 mg/ml — skin quality and hydration, with no volumising purpose |
| OBT / XpresHAn — flexibility and expression | G′ 70–271 Pa · deformability 761–1,442 % |
| Restylane Refyne | HA 20 mg/ml · G′ 70 Pa · 1,442 % — moderate wrinkles and folds |
| Restylane Kysse | HA 20 mg/ml · G′ 160 Pa · 908 % — lips, submucosal plane |
| Restylane Volyme | HA 20 mg/ml · G′ 171 Pa · 930 % — malar volume, supraperiosteal or subcutaneous |
| Restylane Defyne | HA 20 mg/ml · G′ 271 Pa · 761 % — severe wrinkles and folds |
The G′ (0.1 Hz) and deformability (xStrain) values are taken from peer-reviewed literature (J Drugs Dermatol 2024;23(12):1332–1338). Galderma does not publish official rheological values.
Indications and treatment areas
Injection into the supraperiosteal zone or into the subcutis to augment the volume of the cheeks.
- Cheekbones and malar region
- Restoration of midface volume
The indication documented by the manufacturer is malar volume. Use in other areas falls outside the instructions for use and is the responsibility of the practitioner who prescribes it.
Technique and treatment protocol
- Injection plane: supraperiosteal or subcutaneous. It is not indicated for dermal injection.
- Needles included: 2 units of 27G ½" ultra-thin wall.
- Technique: supraperiosteal bolus deposit or fanning retrograde injection in the subcutaneous plane, with low and constant pressure.
- Aspiration prior to injection in accordance with standard clinical protocol; the midface is an area of significant vascular risk.
- Avoid superficial injection: it may produce visible contour irregularities.
Technical data
| Manufacturer | Q-Med AB (Galderma) — Seminariegatan 21, SE-752 28 Uppsala, Sweden |
|---|---|
| Active substance | Cross-linked hyaluronic acid 20 mg/ml, non-animal origin |
| Anaesthetic | Lidocaine hydrochloride 3 mg/ml |
| Technology | OBT™ (XpresHAn Technology™) |
| Vehicle / pH | Phosphate buffer solution, pH 7 |
| Rheology | G′ 171 Pa · deformability 930 % |
| Presentation | 1 pre-filled syringe of 1.0 ml |
| Needles | 2 × 27G ½" ultra-thin wall |
| Treatment plane | Supraperiosteal or subcutaneous |
| Sterilisation | Moist heat (syringe contents) / irradiation (needles) |
| Classification | CE-marked medical device (MDR 2017/745) |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: up to 25 °C. Protect from freezing and from sunlight.
- Do not use after the expiry date stated on the pack.
- Single-use product. Do not reuse or re-sterilise.
- The pack contains: 1 pre-filled plastic syringe of 1.0 ml, 2 sterile needles 27G ½" UTW, traceability labels for the patient record and a blister pack.
Contraindications and warnings
Contraindications (Galderma instructions for use): known hypersensitivity to streptococcal proteins or to any component of the product; history of severe allergies or of anaphylactic reaction; hypersensitivity to lidocaine or to amide-type local anaesthetics; porphyria; active skin inflammation or infection in the area to be treated.
Caution and individual assessment: coagulation disorders or anticoagulant or antiplatelet therapy (increased risk of haematoma and bleeding at the puncture site); history of hypertrophic or keloid scarring; autoimmune disease; presence of permanent implants in the area.
Warnings: do not inject intravascularly or intramuscularly. Intravascular injection may cause embolisation, vascular occlusion, ischaemia, skin necrosis, visual disturbances, blindness or stroke. Aspiration before injecting and a low, constant injection pressure are recommended. Do not mix the gel with other products.
Always consult the instructions for use included in the pack before treatment.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on the manufacturer's official documentation (instructions for use Restylane® Volyme™, Q-Med AB / Galderma). This information sheet does not replace the instructions for use supplied with the product.